Day: December 23, 2022

San Francisco, CA, Dec. 23, 2022 (GLOBE NEWSWIRE) — RocketFuel Blockchain, Inc. (OTCQB: RKFL) (“RocketFuel” or the “Company”), a global provider of payment solutions via ACH bank transfers, Bitcoin and other cryptocurrencies, today announced that it is projecting an 1,300% increase in payment transactions processed for the third fiscal quarter ending December 31, 2022 over its previous fiscal quarter. Management Commentary “More and more people are paying with cryptocurrencies instead of credit cards. Starting in September 2022, we saw a significant acceleration in our number of crypto payment transactions processed each month and our transaction growth is accelerating exponentially. Last quarter, our transaction growth was 10x over the previous quarter, and in the current quarter we project our transaction growth to be at least...

IDC MarketScape for U.S. RCM Service Solutions 2022-2023 Vendor Assessment IDC MarketScape for U.S. RCM Service Solutions 2022-2023 Vendor AssessmentIRVING, Texas, Dec. 23, 2022 (GLOBE NEWSWIRE) — Exela Technologies, Inc. (“Exela”) (NASDAQ: XELA, XELAP), a leading provider of Business Process Automation solutions, today announced that it has been recognized as a ‘Major Player’ in the IDC MarketScape for U.S. RCM Service Solutions 2022-2023 Vendor Assessment. Source: IDC, 2022 Revenue Cycle Management (RCM) is the process by which a health system bills for services and generates revenue. RCM typically covers the entire patient journey, from a patient’s first appointment all the way through to the payor’s acceptance of final payment. This IDC MarketScape assesses RCM service solutions currently available in the U.S. market. This...

MIAMI, FL, Dec. 23, 2022 (GLOBE NEWSWIRE) — Grand Havana Inc. (OTC Pink: GHAV) through its wholly owned subsidiary GH Hospitality Group, LLC today revealed a major land development venture and an exclusive licensing and branding plan in South Florida.  Expanding on the corporate vision recently announced by the new administration, the GHAV directorate will amplify the physical presence of the brand via a land project that was formalized over the last five (5) years.  The new administrations private investment company H&H Coffee Investments, LLC (H&H) has been at the forefront of the negotiations from the outset; leveraging its extensive portfolio of public and private works that include Master-planning, residential and commercial. GHAV, via GH Hospitality and with the support of H&H, is prepared to move swiftly...

ISELIN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) — Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced that it has entered into a Securities Purchase Agreement (“SPA”) with an accredited investor (the “lender”), and pursuant to the SPA, issued the lender an unsecured convertible promissory note (the “Note”) with a face amount of $31,820,000. The closing of the financing is expected to occur on December 28, 2022, subject to satisfaction of closing conditions, including the receipt of at least $25.0 million of equity financing. The proceeds from the Note and a previously announced equity financing, which remains subject to satisfaction of customary closing conditions,...

VANCOUVER, British Columbia, Dec. 23, 2022 (GLOBE NEWSWIRE) — Novo Resources Corp. (“Novo” or the “Company”) (TSX: NVO, NVO.WT & NVO.WT.A) (OTCQX: NSRPF) is pleased to advise of the withdrawal of a recently filed appeal of the Western Australian Environmental Protection Authority’s decision to not assess the Company’s proposed Phase Two Fresh operations1 at the Beatons Creek project (“Beatons Creek”). The proposal to mine Beatons Creek Fresh material will now be assessed and managed by the Western Australian Department of Mines, Industry Regulation and Safety in consultation with other regulatory authorities. ABOUT NOVO Novo explores and develops its prospective land package covering approximately 10,500 square kilometres in the Pilbara region of Western Australia, including the Beatons Creek gold project, along with two joint...

VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, will hold a webcast on December 29, 2022 at 8:00 a.m. Pacific Time (11:00 a.m. Eastern Time) to discuss the performance of leronlimab in its clinical trials and the recent charges against its former CEO Nader Pourhassan, who was previously terminated on January 24, 2022, and has had no affiliation with the Company since that time. Webcast Access InformationDate: Thursday, December 29, 2022Time: 8:00 a.m. Pacific Time / 11:00 a.m. Eastern TimeAccess: https://event.choruscall.com/mediaframe/webcast.html?webcastid=i2RX9JZGThe replay will be available approximately...

NDA supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study NDA includes detailed safety analysis of 2,477 patients with nearly 1,000 patients on study drug for 4 years MORRISTOWN, N.J., Dec. 23, 2022 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for obeticholic acid (OCA) for the treatment of patients with pre-cirrhotic liver fibrosis due to nonalcoholic steatohepatitis (NASH). The resubmission is supported by a robust body of evidence from the OCA NASH clinical development program,...

Fourth quarter 2022                                       14 February 2023 Annual General Meeting 2023                       9 March 2023 First quarter 2023                                          11 May 2023 Second quarter 2023                                     17 August 2023 Third quarter 2023                                         2 November 2023 Fourth quarter 2023                                       8 February 2024 Annual General Meeting 2024                       7 March 2024 Financial results will be disclosed and published after market closing. Please note that dates are subject to change.

–   This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics, and analgesic activity of KUR-101 –   KUR-101 was well tolerated and demonstrated analgesic activity in two experimental pain models –   An assessment of the respiratory impact of KUR-101 was inconclusive as the positive control, oxycodone, failed to separate from placebo –   KUR-101, a deuterated derivative of mitragynine, is a low-potency, partial mu-opioid receptor (MOR) agonist designed to produce therapeutic effects without clinically significant respiratory depression NEW YORK and BERLIN, Dec. 23, 2022 (GLOBE NEWSWIRE) — atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today...